LITAF and membrane repair in infection and inflammation
Official title: LITAF regulation of membrane repair and inflammation
Funded at Benaroya Research Inst at Virginia Mason · NIH-11334316 · Data updated 2026-11-12
A patient-friendly description of how LITAF may help cells repair damaged membranes during infections and inflammatory conditions, potentially reducing harmful inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $846,106 |
| NIH project number | 5R01AI177971-03 |
| Project ID | NIH-11334316 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with inflammatory or infectious lung conditions where membrane damage and innate immunity play a key role, or individuals who could provide samples for related studies.
✕Less likely to help
Patients without inflammatory or infectious conditions related to membrane damage may not directly benefit from this specific research.
What this research studies
This project looks at how cells fix damaged cell membranes when they're attacked by bacteria and their toxins. It centers on a protein called LITAF and how it might coordinate membrane repair with the body’s innate immune response. The researchers will use genetic screening and lab models to uncover how LITAF is activated, how it works to protect cells, and how it affects lung inflammation during infection. If successful, the work could point to new ways to prevent excessive inflammation while preserving the body’s defense against bacteria.
Why it matters
Potential benefit: Findings could lead to new approaches to reduce harmful inflammation during bacterial infections and improve outcomes for patients with inflammatory lung diseases.
How similar studies have gone: Previous work has shown that membrane repair pathways influence inflammation, supporting potential benefits from targeting LITAF.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Lacy-Hulbert, Adam — Benaroya Research Inst at Virginia Mason
- Study coordinator: Lacy-Hulbert, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.